Top Markets
#1 Official Trump Official Trump +32.45%
#2 EXOD EXOD +22.08%
#3 Movement Movement +21.25%
#4 Mubarak Mubarak +19.14%
#5 POL (ex-MATIC) POL (ex-MATIC) +18.85%
#6 Wrapped POL Wrapped POL +18.83%
#7 Pearl Pearl +17.90%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +17.22%
#9 Melania Meme Melania Meme +16.21%
#10 Glidr Glidr +11.25%
Coin of the day
Official Trump Official Trump
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
MaaT Pharma S.A. MaaT Pharma S.A.

MaaT Pharma S.A.

MAAT
Clasificación en acciones #23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Precio por acción
$3.78
Última sincronización: 2026-08-21
Capitalización bursátil
$71.20M
Cambio (1 día)
2.24%
Cambio (1 año)
-43.37%
País
FR
Comercio MaaT Pharma S.A. (MAAT)

Categoría

Healthcare
Ganancias de MaaT Pharma S.A. (MAAT)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di MaaT Pharma S.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de MaaT Pharma S.A. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH